Skip to content
lifestyle.newsblaze.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Pharmazz, Inc.
Pharmazz, Inc. Receives U.S. FDA IND Clearance to Initiate Phase 3 Clinical Trial of Sovateltide in Traumatic Brain Injury
September 30, 2026
Pharmazz Completes Enrollment in 160-Patient Phase 4 Trial of Sovateltide in Acute Ischemic Stroke
September 28, 2026
Pharmazz, Inc. Receives U.S. FDA Orphan Drug Designation for Sovateltide for the Treatment of Neonatal Hypoxic-Ischemic Encephalopathy (NHIE)
September 14, 2026
Pharmazz, Inc. Appoints Ajay Bansal as Chief Financial Officer
May 14, 2026
Pharmazz Presents Positive Phase IV Interim Analysis of Sovateltide for Acute Ischemic Stroke at the International Stroke Conference 2026
February 10, 2026